Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity

Prostate cancer (PCa) is characterized as a “cold tumor” with limited immune responses, rendering the tumor resistant to immune checkpoint inhibitors (ICI). Therapeutic messenger RNA (mRNA) vaccines have emerged as a promising strategy to overcome this challenge by enhancing immune reactivity and si...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Zhen Xu, Ze-Xiu Xiao, Jing Wang, Hao-Wei Qiu, Fei Cao, Shi-Qiang Zhang, Yuan-Dong Xu, Han-Qi Lei, Heng Xia, Yun-Ru He, Gao-Feng Zha, Jun Pang
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Taylor & Francis Group 2024-12-01
Reeks:	OncoImmunology
Onderwerpen:	Immunotherapy lipid nanoparticles mRNA vaccine prostate cancer tumor-associated antigens
Online toegang:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2373526
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!